ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
- Webcast on December 17 at 8:00 AM EST to feature ALX Oncology leadership and study principal investigator Alberto J. Montero, MD, MBA
- 網絡直播將於12月17日上午8:00（美國東部時間）舉行，屆時將介紹ALX Oncology的領導層和主要研究員阿爾貝託·J·蒙特羅（Alberto J. Montero）醫學博士，MBA。
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology" or "the Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, announced that the company will host a virtual event on Tuesday, December 17, at 5:00 AM PST / 8:00 AM EST to discuss the first data from a Phase 1b/2 clinical trial evaluating the company's investigational CD47-blocker evorpacept in combination with Jazz Pharmaceuticals' zanidatamab in heavily pretreated patients with metastatic breast cancer. The data were featured today in a spotlight poster presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS). The poster is now available on the ALX Oncology site under Publications.
南舊金山，加利福尼亞州，2024年12月12日（環球新聞通訊社） — ALX Oncology Holdings Inc.（"ALX Oncology"或"公司"）（納斯達克：ALXO），是一家處於臨床階段的生物技術公司，致力於推進通過增強免疫系統治療癌症並延長患者生命的療法。公司宣佈將於2024年12月17日星期二美國時間下午5:00 / 上午8:00 舉辦一場虛擬活動，討論來自一項評估公司研究性CD47抑制劑evorpacept與爵士製藥的zanidatamab聯合使用的Phase 1b/2臨床試驗的首次數據，參與者爲重度預處理的轉移性乳腺癌患者。今日的數據在2024年聖安東尼奧乳腺癌研討會（SABCS）上以重點海報的形式展示。該海報現在可以在ALX Oncology的網站上的出版物部分查看。
During the virtual company event, Alberto J. Montero, MD, MBA, Clinical Director, Breast Cancer Medical Oncology Program, Diana Hyland Endowed Chair for Breast Cancer, and Professor of Medicine at University Hospitals Seidman Cancer Center, Case Western Reserve University, and the study's principal investigator, will provide an overview of the data presented at SABCS 2024 and participate in a fireside chat with Alan Sandler, MD, ALX Oncology's Chief Medical Officer. Jason Lettmann, Chief Executive Officer at ALX Oncology, will provide opening and closing remarks, highlighting progress and upcoming milestones for the company's evorpacept clinical program.
在虛擬公司活動中，阿爾貝託·J·蒙特羅（Alberto J. Montero）醫學博士，MBA，臨床主任，乳腺癌醫療腫瘤學項目，戴安娜·海蘭德乳腺癌教育基金會主席，凱斯西儲大學西丹癌症中心醫學教授以及該研究的主要研究員，將提供2024年SABCS上展示的數據概述，並與ALX Oncology的首席醫療官艾倫·桑德勒（Alan Sandler）醫學博士進行爐邊談話。ALX Oncology首席執行官賈森·萊特曼（Jason Lettmann）將發表開幕和閉幕講話，強調公司evorpacept臨床項目的進展和即將到來的里程碑。
The event will be webcast live and can be accessed by visiting the Investors section of ALX Oncology's website at and selecting Events under News and Events. To participate in the live event, please register using this link: . An archived webcast will be available following the event.
該活動將直播，並可通過訪問ALX Oncology網站的投資者部分，選擇新聞和活動下的活動來訪問。要參與直播活動，請使用此鏈接進行註冊：。活動結束後將提供一個存檔的網絡直播。
About ALX Oncology
關於ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives. ALX Oncology's lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at and on LinkedIn @ALX Oncology.
ALX Oncology（納斯達克：ALXO）是一家臨床階段的生物技術公司，致力於開發增強免疫系統的療法，以治療癌症並延長患者的生命。ALX Oncology的主要治療候選藥物evorpacept展示了作爲未來免疫腫瘤學的基石療法的潛力。Evorpacept目前正在多項持續進行的臨床試驗中評估，適用於多種癌症適應症。更多信息請訪問以及在LinkedIn上關注@ALX Oncology。
CONTACT: Company Contact:
Caitlyn Doherty, Manager, Corporate Communications, ALX Oncology
cdoherty@alxoncology.com
(650) 466-7125
Media Contact:
Audra Friis, Sam Brown, Inc.
audrafriis@sambrown.com
(917) 519-9577
聯繫方式：公司聯繫人：
凱特琳·多赫提，ALX Oncology公司通信經理
cdoherty@alxoncology.com
(650) 466-7125
媒體聯繫人：
奧德拉·弗里斯，薩姆·布朗公司
audrafriis@sambrown.com
(917) 519-9577
譯文內容由第三人軟體翻譯。
